Full Text Available
Note: Clicking the button above will open the full text document at the original institutional repository in a new window.
Neoadjuvant endocrine therapy for estrogen receptor positive breast cancer in an African setting
Background Several studies have reported response rates for ER positive cancers on neoadjuvant endocrine therapy (NET), with lower toxicity compared to neoadjuvant chemotherapy (NCT). During the first wave of the COVID pandemic, clinician preference for NET increased significantly, buying time for h...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | |
| Format: | Thesis |
| Language: | English |
| Published: |
Division of General Surgery
2023
|
| Subjects: | |
| Tags: |
No Tags, Be the first to tag this record!
|
| _version_ | 1867613206990553088 |
|---|---|
| access_status_str | Open Access |
| author | Molabe, Hunadi |
| author2 | Malherbe, Francois |
| author_browse | Malherbe, Francois Molabe, Hunadi |
| author_facet | Malherbe, Francois Molabe, Hunadi |
| author_sort | Molabe, Hunadi |
| collection | Thesis |
| description | Background Several studies have reported response rates for ER positive cancers on neoadjuvant endocrine therapy (NET), with lower toxicity compared to neoadjuvant chemotherapy (NCT). During the first wave of the COVID pandemic, clinician preference for NET increased significantly, buying time for hospital recovery before proceeding to surgery. To date, no studies have yet explicitly reported on the use of NET in an African context. Methods This study was a retrospective review, looking at breast cancer patients who received NET between 01 March 2019 to 31 December 2020 at Groote Schuur Hospital. Patients were included if they were female, older than 18 years, ER positive, and had a biopsy-proven breast cancer less than 50mm in size on clinical exam. Results There were 16 patients included in the study, of which all were female. The mean age was 59 years (range 41-75). When comparing the histological measurement to initial size on imaging, 7 patients had an excellent response to NET with tumours that decreased in size, whereas 9 patients had tumours that increased in size despite NET. There was no statistically significant difference between the two groups in terms of patient and pre-treatment tumour characteristics, pathological results, endocrine therapy, surgical therapy, or adjuvant oncological therapy. For the 9 patients who had progression on NET, the post resection median tumour size was more than double the pre-NET tumour size, as determined on imaging. Conclusion Until further studies can be performed in this setting, NET should be used with caution in situations where there will be a significant delay to surgery. |
| format | Thesis |
| id | oai:open.uct.ac.za:11427/37565 |
| institution | University of Cape Town (South Africa) |
| language | eng |
| last_indexed | 2026-06-10T12:32:27.580Z |
| license_str | Not specified — see source repository |
| provenance_str_mv | Harvested via OAI-PMH from UCTD — University of Cape Town Open Access Repository |
| publishDate | 2023 |
| publishDateRange | 2023 |
| publishDateSort | 2023 |
| publisher | Division of General Surgery |
| publisherStr | Division of General Surgery |
| record_format | dspace |
| source_str | UCTD — University of Cape Town Open Access Repository |
| spelling | oai:open.uct.ac.za:11427/37565 Neoadjuvant endocrine therapy for estrogen receptor positive breast cancer in an African setting Molabe, Hunadi Malherbe, Francois Surgery Background Several studies have reported response rates for ER positive cancers on neoadjuvant endocrine therapy (NET), with lower toxicity compared to neoadjuvant chemotherapy (NCT). During the first wave of the COVID pandemic, clinician preference for NET increased significantly, buying time for hospital recovery before proceeding to surgery. To date, no studies have yet explicitly reported on the use of NET in an African context. Methods This study was a retrospective review, looking at breast cancer patients who received NET between 01 March 2019 to 31 December 2020 at Groote Schuur Hospital. Patients were included if they were female, older than 18 years, ER positive, and had a biopsy-proven breast cancer less than 50mm in size on clinical exam. Results There were 16 patients included in the study, of which all were female. The mean age was 59 years (range 41-75). When comparing the histological measurement to initial size on imaging, 7 patients had an excellent response to NET with tumours that decreased in size, whereas 9 patients had tumours that increased in size despite NET. There was no statistically significant difference between the two groups in terms of patient and pre-treatment tumour characteristics, pathological results, endocrine therapy, surgical therapy, or adjuvant oncological therapy. For the 9 patients who had progression on NET, the post resection median tumour size was more than double the pre-NET tumour size, as determined on imaging. Conclusion Until further studies can be performed in this setting, NET should be used with caution in situations where there will be a significant delay to surgery. 2023-03-30T12:28:41Z 2023-03-30T12:28:41Z 2022 2023-03-30T10:17:45Z Master Thesis Masters MMed http://hdl.handle.net/11427/37565 eng application/pdf Division of General Surgery Faculty of Health Sciences |
| spellingShingle | Surgery Molabe, Hunadi Neoadjuvant endocrine therapy for estrogen receptor positive breast cancer in an African setting |
| thesis_degree_str | Master's |
| title | Neoadjuvant endocrine therapy for estrogen receptor positive breast cancer in an African setting |
| title_full | Neoadjuvant endocrine therapy for estrogen receptor positive breast cancer in an African setting |
| title_fullStr | Neoadjuvant endocrine therapy for estrogen receptor positive breast cancer in an African setting |
| title_full_unstemmed | Neoadjuvant endocrine therapy for estrogen receptor positive breast cancer in an African setting |
| title_short | Neoadjuvant endocrine therapy for estrogen receptor positive breast cancer in an African setting |
| title_sort | neoadjuvant endocrine therapy for estrogen receptor positive breast cancer in an african setting |
| topic | Surgery |
| url | http://hdl.handle.net/11427/37565 |
| work_keys_str_mv | AT molabehunadi neoadjuvantendocrinetherapyforestrogenreceptorpositivebreastcancerinanafricansetting |